Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...
Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market ...
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...
One of our grandsons is active in the Cub Scout program. His mom, our daughter, has found herself thrust into the role of outdoor activities manager for the den. She asked if I wanted to tag along ...
Q3 2025 Management View Daniel O'Day, Chairman & CEO, stated that "our third quarter earnings underscore the growing momentum you're seeing from Gilead today, which is driven by our strong portfolio ...
Nagpur: Union Minister Nitin Gadkari on Friday unveiled plans for a state-of-the-art commercial hub in city, modelled on Mumbai's Bandra Kurla Complex (BKC). It will be developed on 19 hectares of ...
Commercial litigation is notoriously expensive. It’s not unusual for a case to take years and cost hundreds of thousands of dollars in legal bills, just to get to trial. That financial barrier causes ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new commercial building has ...
VENICE, Fla.--(BUSINESS WIRE)--Commercial Residential Aluminum (“CRA”), a portfolio company of Garden City Equity (“Garden City”), announced today that it has acquired American Lightscapes, a Sarasota ...
Two North Jersey commercial properties sales were announced in the past week, each for millions of dollars — an office building in Montvale and a warehouse in Florham Park — despite the reduced demand ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Gilead Sciences, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback